Plus Therapeutics Confronts Nasdaq Compliance Issue
Recently, Plus Therapeutics, Inc. (Nasdaq: PSTV) announced that it received a notification from Nasdaq concerning a compliance issue. This notification, issued on a specific date, informed the Company of its non-compliance regarding the timely filing of its Quarterly Report on Form 10-Q, which is due for the ending period. This situation arises as Nasdaq mandates all listed companies to submit required financial reports to the U.S. Securities and Exchange Commission (SEC) punctually.
Understanding the Notification
The notification serves as a formal reminder that companies must adhere to specific regulations regarding financial disclosures. It indicates that Plus Therapeutics failed to meet the requirement outlined in Nasdaq Listing Rule 5250(c)(1). Importantly, while this notification raises concerns about compliance, it does not alter the Company’s current listing status on Nasdaq.
Next Steps for Compliance
In response to this notification, Plus Therapeutics is tasked with formulating a plan to recover its compliance status. This plan must be submitted by a given date, after which Nasdaq may grant an extension to allow the Company additional time to rectify its filing status. The possible extension can last up to 180 calendar days.
Company's Commitment to Filing
Plus Therapeutics is actively working to ensure that the Quarterly Report is completed and filed as soon as possible. The Company emphasizes its commitment to returning to a routine filing schedule for its reports throughout the year as it navigates this challenge.
About Plus Therapeutics
Headquartered in Houston, Texas, Plus Therapeutics focuses on developing innovative treatments for challenging cancers that affect the central nervous system. The Company’s approach combines targeted radiotherapeutics with beta radiation and innovative drug delivery methods. Their leading programs currently address severe conditions like leptomeningeal metastases and recurrent glioblastoma, which affect numerous patients.
Moreover, Plus Therapeutics has established a robust supply chain thanks to strategic partnerships facilitating the development, manufacturing, and potential commercialization of its groundbreaking products. Their pipeline reflects a determined effort to enhance clinical outcomes for patients dealing with difficult-to-treat cancers.
Forward-Looking Statements and Trends
As is typical in the biotech sector, Plus Therapeutics has issued a blend of forward-looking statements regarding its plans and projected timelines. Such statements encompass expectations regarding the completion and timely submission of financial reports and compliance plans required by Nasdaq.
These projections could be influenced by various uncertainties including the regulation, market dynamics, and internal operational efficiencies. As the Company navigates through these waters, it remains committed to keeping its stakeholders informed.
Contact Information
Those interested in learning more or seeking more detailed information can reach out directly to Andrew Sims, CFO of Plus Therapeutics, Inc., at 737-255-7194 or via email.
Frequently Asked Questions
What compliance issue did Plus Therapeutics encounter?
Plus Therapeutics received a notification from Nasdaq regarding a delay in filing their Quarterly Report on Form 10-Q.
How is Plus Therapeutics addressing the compliance issue?
The Company is actively working on a compliance plan that must be submitted to Nasdaq, along with their intention to file the necessary reports timely.
Are there any immediate consequences for the Company?
Currently, there are no immediate consequences affecting the listing of Plus Therapeutics on Nasdaq, but timely compliance is crucial to maintain their listing status.
What is the focus of Plus Therapeutics?
Plus Therapeutics is dedicated to developing targeted therapies for challenging cancers, particularly those impacting the central nervous system.
Who can be contacted for more information about Plus Therapeutics?
Prospective inquiries can be directed to Andrew Sims, CFO, at Plus Therapeutics for more information about the company and its current status.
